PDCD1 and cancer: Recent advances in cancer treatment are emerging from new therapies that target T-cell inhibitory receptors, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) (17, 18).